These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27709279)

  • 21. High-Spatial-Resolution Diffusion MRI in Parkinson Disease: Lateral Asymmetry of the Substantia Nigra.
    Zhong Z; Merkitch D; Karaman MM; Zhang J; Sui Y; Goldman JG; Zhou XJ
    Radiology; 2019 Apr; 291(1):149-157. PubMed ID: 30777809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.
    Bergsland N; Zivadinov R; Schweser F; Hagemeier J; Lichter D; Guttuso T
    Mov Disord; 2019 Jul; 34(7):1006-1013. PubMed ID: 31180615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Substantia nigra fractional anisotropy changes confirm the PD at-risk status of patients with idiopathic smell loss.
    Haehner A; Schöpf V; Loureiro A; Linn J; Reichmann H; Hummel T; Kitzler HH
    Parkinsonism Relat Disord; 2018 May; 50():113-116. PubMed ID: 29477459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study.
    Menke RA; Scholz J; Miller KL; Deoni S; Jbabdi S; Matthews PM; Zarei M
    Neuroimage; 2009 Aug; 47(2):435-41. PubMed ID: 19447183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis.
    Wang X; Zhang Y; Zhu C; Li G; Kang J; Chen F; Yang L
    Neurol Sci; 2019 Dec; 40(12):2479-2489. PubMed ID: 31392640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case control study of diffusion tensor imaging in Parkinson's disease.
    Chan LL; Rumpel H; Yap K; Lee E; Loo HV; Ho GL; Fook-Chong S; Yuen Y; Tan EK
    J Neurol Neurosurg Psychiatry; 2007 Dec; 78(12):1383-6. PubMed ID: 17615165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic value of combined assessment of olfaction and sustantia nigra hyperechogenicity for Parkinson's disease.
    López Hernández N; García Escrivá A; Shalabi Benavent M
    Neurologia; 2015 Oct; 30(8):496-501. PubMed ID: 24839905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease.
    Cosottini M; Frosini D; Pesaresi I; Costagli M; Biagi L; Ceravolo R; Bonuccelli U; Tosetti M
    Radiology; 2014 Jun; 271(3):831-8. PubMed ID: 24601752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD).
    Esterhammer R; Seppi K; Reiter E; Pinter B; Mueller C; Kremser C; Zitzelsberger T; Nocker M; Scherfler C; Poewe W; Schocke M
    PLoS One; 2015; 10(12):e0145493. PubMed ID: 26713760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance imaging assessment of substantia nigral iron deposition in Parkinson's disease: a meta-analysis.
    Liu GL; Zhang HW; Zha CB; Fan TW; Chen ST; Shen TT; He K
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):899-906. PubMed ID: 38375696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Locus coeruleus and substantia nigra neuromelanin magnetic resonance imaging differentiates Parkinson's disease and essential tremor.
    Wang X; Huang P; Haacke EM; Liu Y; Zhang Y; Jin Z; Li Y; Xu Q; Liu P; Chen S; He N; Yan F
    Neuroimage Clin; 2023; 38():103420. PubMed ID: 37141646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited.
    Langley J; Huddleston DE; Merritt M; Chen X; McMurray R; Silver M; Factor SA; Hu X
    Hum Brain Mapp; 2016 Jul; 37(7):2547-56. PubMed ID: 27029026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging nigral pathology and clinical progression in Parkinson's disease.
    Du G; Lewis MM; Sen S; Wang J; Shaffer ML; Styner M; Yang QX; Huang X
    Mov Disord; 2012 Nov; 27(13):1636-43. PubMed ID: 23008179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Accuracy of Transcranial Sonography of the Substantia Nigra in Parkinson's disease: A Systematic Review and Meta-analysis.
    Li DH; He YC; Liu J; Chen SD
    Sci Rep; 2016 Feb; 6():20863. PubMed ID: 26878893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease.
    van de Loo S; Walter U; Behnke S; Hagenah J; Lorenz M; Sitzer M; Hilker R; Berg D
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1087-92. PubMed ID: 20543186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease.
    Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does normal substantia nigra echogenicity make a difference in Parkinson's disease diagnosis? A real clinical practice follow-up study.
    Alonso-Canovas A; Lopez-Sendon Moreno JL; Buisan J; Sainz de la Maza S; Costa-Frossard L; Garcia-Ribas G; de Felipe-Mimbrera A; Matute-Lozano MC; Zarza Sanz B; Toledano Delgado R; Corral I; Masjuan J; Martinez-Castrillo JC
    J Neurol; 2018 Oct; 265(10):2363-2369. PubMed ID: 30116942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.
    Castellanos G; Fernández-Seara MA; Lorenzo-Betancor O; Ortega-Cubero S; Puigvert M; Uranga J; Vidorreta M; Irigoyen J; Lorenzo E; Muñoz-Barrutia A; Ortiz-de-Solorzano C; Pastor P; Pastor MA
    Mov Disord; 2015 Jun; 30(7):945-52. PubMed ID: 25772492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.